Comparative Pharmacology
Head-to-head clinical analysis: BENZAMYCIN versus CLINDETS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZAMYCIN versus CLINDETS.
BENZAMYCIN vs CLINDETS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It also acts as a competitive inhibitor of bacterial ribosomal RNA methyltransferases.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
Clindamycin: 150-450 mg orally every 6 hours; 600-900 mg IV every 8 hours. Max: 1.8 g/day for severe infections.
None Documented
None Documented
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
Terminal elimination half-life is 2.4-3 hours in adults; prolonged to 4-6 hours in severe hepatic impairment.
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Approximately 10% of the dose is excreted unchanged in urine; the remainder is hepatically metabolized and eliminated via bile (fecal: ~40%) and urine as inactive metabolites.
Category C
Category C
Topical Antibiotic
Topical Antibiotic